La catena delle opzioni mostra i dati chiave delle opzioni azionarie di iQIYI a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per iQIYI..

iQIYI (NASDAQ:IQ) Azioni, Catena delle Opzioni

IQIYI INC-ADR

iQIYI

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

SCOR

SGRP

Scopri le tre azioni tecnologiche ipervendute con alto potenziale di crescita che potrebbero rafforzare il tuo portafoglio questo mese.

3 azioni che dovresti acquistare nel mese di settembre

iQIYI Inc

Everipedia

IQ-AI Ltd

FlexShares Trust Intl Quality Dividend Defensive Index Fd

FlexShares International Quality Dividend Index Fund

WisdomTree International Quality Dividend Growth Fund

FlexShares International Quality Dividend Dynamic Index Fund

IQE PLC

IQGeo Group PLC

NYLI MacKay High Income ETF

Invesco Quality Municipal Income Trust Common Stock

Invesco Quality Municipal Income Trust

IndexIQ ETF Trust NYLI 500 International ETF

iShares MSCI Intl Quality Factor ETF

Franklin Intelligent Machines ETF

IQeon

Inteliqo Ltd

ProShares Nasdaq-100 High Income ETF

NYLI CBRE Real Assets ETF

NYLI Candriam International Equity ETF

NYLI Candriam U.S. Mid Cap Equity ETF

iQSTEL Inc

IQSTEL INC NEW by iQSTEL Inc.

NYLI Candriam U.S. Large Cap Equity ETF

IQVIA Holdings Inc

iQ International AG

Wall Street's reaction to <a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns">Moody's downgrade of U.S. debt </a>is turning into a tale of two titans. On one end, you have Ray Dalio — founder of Bridgewater Associates — warning that the downgrade grossly understates the true risk of owning U.S. debt.
On the other hand, there&#8217;s Tom Lee of Fundstrat. Lee brushed the downgrade off as a "non-event" and told investors to go shopping for stocks.
Moody's cut the U.S. credit rating from Aaa to Aa1, following in the footsteps of S&amp;P in 2011 and Fitch in 2023. With this move, the U.S. officially loses its AAA status across the board. 
But is it a flashing red signal or just another headline?
Read Also: <a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">Ray Dalio&#8217;s Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?</a>
<h2 class="wp-block-heading">Ray Dalio: The Real Threat Isn&#8217;t Default, It Is&#8230;</h2>
Dalio didn't mince words. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Re the U.S. debt downgrade, you should know that credit ratings understate credit risks because they only rate the risk of the government not paying its debt. They don&#39;t include the greater risk that the countries in debt will print money to pay their debts thus causing holders…
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1924452875108839862?ref_src=twsrc%5Etfw">May 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He argued the real threat isn't default, but dilution — central banks printing money to meet obligations. 
"For those who care about the value of their money," he posted on X, "the risks for U.S. government debt are greater than the rating agencies are conveying." Translation? The downgrade misses the bigger picture: currency debasement.
<h2 class="wp-block-heading">Tom Lee: Downgrade = Largely &#8216;Non-Event&#8217;</h2>
Tom Lee, meanwhile, is telling clients to stay calm and keep buying. Like those before, he says this downgrade is unlikely to trigger panic. History might just be on his side — after S&amp;P's downgrade in 2011 and Fitch's in 2023, the S&amp;P 500 plunged roughly 10% in the short term but rallied over 35% within a year in both cases.
So what now? If Dalio's right, long-term bondholders could face slow bleed-through inflation, not default. But if Lee's playbook holds, a short-term dip could be just the setup bulls need.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/05/45491935/history-says-sp-500-could-fall-10-after-rating-downgrade-but-rally-35-after">S&amp;P 500 History Suggests 10% Drop After Downgrade — Followed By 35% Rally</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Hedge Funds

Economics

Dalio Sees Danger, Tom Lee Sees Dip-Buy: Who's Right About The US Credit Downgrade?

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $320 to $330.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $330

WIIM

NVAX

Moderna shares are trading higher after the company announced it received approval from the FDA for its COVID-19 vaccine and unlocked a milestone $175 million payment from Sanofi SA.

Morgan Stanley analyst Brian Nowak maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Overweight and raises the price target from $210 to $265.

TTWO

Morgan Stanley Maintains Overweight on Take-Two Interactive, Raises Price Target to $265

Morgan Stanley analyst Patrick Wood maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Equal-Weight and raises the price target from $240 to $260.

Morgan Stanley Maintains Equal-Weight on Steris, Raises Price Target to $260

TXNM

TXNM Energy shares are trading higher after the company announced it entered into an agreement to be acquired by Blackstone Infrastructure in a deal worth $11.5 billion.

Morgan Stanley analyst Bob Huang maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Equal-Weight and raises the price target from $85 to $90.

SIGI

Morgan Stanley Maintains Equal-Weight on Selective Insurance Gr, Raises Price Target to $90

<a href="https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html" title="https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html">https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html</a>

Biotech

General

AstraZeneca Announces Statistically Significant And Clinically Meaningful BATURA Phase III Trial Results Provide New Evidence For Airsupra As Standard Of Care For As-Needed Rescue Treatment In Asthma; Says Airsupra Demonstrated A 47% Reduction In The Risk Of Severe Exacerbations In Mild Asthma Compared With Albuterol Alone

Since late December 2024, there's been a renewed buzz around Japanese equities. Major institutions like JP Morgan, BlackRock, and several hedge funds have been increasing their exposure to Japanese Equities. However, when we apply the Adhishthana Principles our proprietary system, the picture looks far less bullish than popular sentiment would suggest.
While fund inflows and near-term outperformance have indeed supported the Nikkei 225, our readings indicate that this might be premature optimism. According to the Adhishthana model, Japanese equities may not offer compelling long-term upside until late 2028 or early 2029.
<h3 class="wp-block-heading">What the Adhishthana Principles Reveal</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="542" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050720/NIKKEI-Chart.png" alt="NIKKEI 225 Adhishthana Weekly Chart" class="wp-image-13055" style="width:788px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050720/NIKKEI-Chart.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050720/NIKKEI-Chart-300x136.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050720/NIKKEI-Chart-1024x463.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050720/NIKKEI-Chart-768x347.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 1 NIKKEI 225 Weekly Chart</figcaption></figure>
When we ran the Adhishthana cycles on the weekly Nikkei 225 chart, we found the index currently in Phase 11 (C11) of the standard 18-cycle Adhishthana framework. Since it corrected below its C10 midpoint, this implies the peak creation of Himalayan Ascent is already complete. Depending on how C12 unfolds, which begins on August 4, 2025, we anticipate a sell-off rather than a breakout, supporting a more cautious stance.
Looking at the monthly chart, the Nikkei is currently in Phase 5 (C5). While Phase 1 through 4 aligned with the model, Phase 5 has deviated, particularly since it failed to test the Phase 4 low of 24,681. This break in adherence to the model&#8217;s progression suggests a lack of confirmation for sustained bullish momentum.
As per the monthly cycle, we recommend avoiding major exposure until Phase 6 completes its first 24 bars on January 31, 2029. Post that we'll have the Level of Nirvana, giving us a clearer long-term picture.
<h3 class="wp-block-heading">Nikkei 225 Constituents Reflect Similar Weakness</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="928" height="568" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051817/Adhishthana-Dash.png" alt="Adhishthana Dashboard" class="wp-image-13061" style="width:562px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051817/Adhishthana-Dash.png 928w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051817/Adhishthana-Dash-300x184.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051817/Adhishthana-Dash-768x470.png 768w" sizes="(max-width: 928px) 100vw, 928px" /></figure>
A deeper look at key Nikkei components validates the broader caution:
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="644" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050836/Fast-Retailing.png" alt="Fast Retailing Adhishthana Weekly Chart" class="wp-image-13056" style="width:783px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050836/Fast-Retailing.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050836/Fast-Retailing-300x161.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050836/Fast-Retailing-1024x550.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050836/Fast-Retailing-768x412.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 2 Fast Retailing Co Ltd. Weekly Chart</figcaption></figure>
Fast Retailing is in Phase 13 of 18. While the bullish move from May 2022 was fueled by "The Adhishthana Himalayan Formation," the structure's ascent is now achieved. Until Phase 14 concludes, the risk-reward is not compelling.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="620" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050943/Tokyo-electron.png" alt="Tokyo Electron Adhishthana Weekly Chart" class="wp-image-13057" style="width:805px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050943/Tokyo-electron.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050943/Tokyo-electron-300x155.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050943/Tokyo-electron-1024x529.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19050943/Tokyo-electron-768x397.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 3 Tokyo Electron Weekly Chart</figcaption></figure>
Tokyo Electron, also in Phase 13, failed to break its Phase 11 high during Phase 12. This typically signals limited upside in the current phase. 
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="574" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051109/Advantest-corp.png" alt="Advantest Adhishthana Weekly Chart" class="wp-image-13058" style="width:801px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051109/Advantest-corp.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051109/Advantest-corp-300x144.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051109/Advantest-corp-1024x490.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051109/Advantest-corp-768x367.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 4 Advantest Corp Weekly Chart</figcaption></figure>
Advantest Corp is in Phase 3, a Yajna formation cycle, which explains its correction since January 27. We expect mild bullish behavior only until November 24, 2025, before a new assessment is required. 
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="568" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051207/Softbank-Group-Corp.png" alt="SoftBank Group Corp Adhishthana Weekly Chart" class="wp-image-13059" style="width:807px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051207/Softbank-Group-Corp.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051207/Softbank-Group-Corp-300x142.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051207/Softbank-Group-Corp-1024x485.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051207/Softbank-Group-Corp-768x364.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 5 SoftBank Group Corp Weekly Chart</figcaption></figure>
SoftBank is likewise in Phase 13. We're avoiding exposure here until July 27, 2025, awaiting clarity in Phase 14. 
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="509" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051250/Kiddi-Corporation.png" alt="Kiddi Corporation Adhishthana Weekly Chart" class="wp-image-13060" style="width:825px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051250/Kiddi-Corporation.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051250/Kiddi-Corporation-300x127.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051250/Kiddi-Corporation-1024x434.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19051250/Kiddi-Corporation-768x326.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 6 Kiddi Corporation</figcaption></figure>
KDDI Corp, in Phase 11, may still be in the early stages of a Himalayan formation, but we're advising clients to wait until the phase concludes due to expected near-term corrections. We expect a sell-off sometime towards the end of Phase 11 or the onset of Phase 12. 
<h3 class="wp-block-heading">Strategic Portfolio Guidance</h3>
Combining weekly and monthly outlooks, and correlating individual component phases back to the Nikkei index, the Adhishthana model does not support increasing exposure to Japanese equities at this stage. Our next key portfolio checkpoint is February 21, 2027, when Weekly Phase 14 on the Nikkei completes. The critical long-term signal arrives on February 1, 2029, when the Nirvana level will be identified on the monthly charts. Which will guide our exposure for the next 40 years.&nbsp;
Despite the institutional push, many of our clients are using the current strength to reduce, not increase, their Japanese equity positions. The Adhishthana Principles suggest caution at current levels.&nbsp;

Asia

Equities

Global

Opinion

Why Institutional Optimism On Japanese Equities Could Be Mistimed

ZIM Integrated Shipping Services shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

Morgan Stanley analyst Bob Huang maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Overweight and raises the price target from $78 to $80.

RYAN

Morgan Stanley Maintains Overweight on Ryan Specialty Hldgs, Raises Price Target to $80

Sunrun shares are trading lower amid reports that the company may face an earlier end to its tax credits.

Citigroup analyst Scott Gruber maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and raises the price target from $42 to $44.

Citigroup Maintains Neutral on Occidental Petroleum, Raises Price Target to $44

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression
KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025
KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25
Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively
WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ir2Vj3zElLJx9JDnLlTWpeimwJd7lWvFMeJkbQr8yOO6owzBCJ2VXguG4rKo_PAs-xh4iCoaY9LNaw9cv8sC8udiq6Zrjaq2_uZ5CTlMRY8=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of additional preclinical data for KT-621, its potent, selective, oral STAT6 degrader and the first STAT6 targeted medicine to enter clinical development. The new asthma efficacy mouse model data showed both prevention of disease progression as well as reversal of established disease, building upon the compelling preclinical characterization of KT-621 as a potential once daily, oral treatment for asthma and other Th2 allergic and atopic diseases. These data were presented at the American Thoracic Society (ATS) International Conference being held May 16-21, 2025, in San Francisco, CA.

KYMR

Kymera Therapeutics Presents Addl Preclinical Data For KT-621, Oral STAT6 Degrader At American Thoracic Society International Conference

TECX

Tectonic Therapeutics shares are trading higher after the company announced it presented full Phase 1b results for TX45.

CTMX

CytomX Therapeutics shares are trading higher after the company announced it dosed its first patient in the Phase 1 study of CX-801 plus KEYTRUDA.

Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) has outperformed the market over the past 20 years by 5.73% on an annualized basis producing an average annual return of 14.05%. Currently, Accenture has a market capitalization of $199.93 billion. 
Buying $1000 In ACN: If an investor had bought $1000 of ACN stock 20 years ago, it would be worth $14,285.59 today based on a price of $319.14 for ACN at the time of writing.
<h3>Accenture's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747671311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Accenture 20 Years Ago Would Be Worth This Much Today

Citigroup analyst Scott Gruber maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Neutral and raises the price target from $36 to $44.

Citigroup Maintains Neutral on California Resources, Raises Price Target to $44

Wall Street's <a href="https://www.benzinga.com/topic/billionaires">billionaire brigade hit</a> turbulence in the first quarter of 2025. From Warren Buffett to George Soros, even the most iconic names couldn't dodge the drawdowns as markets rotated and profit-taking weighed down performance.
Buffett's Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) <a href="https://whalewisdom.com/dashboard2/search/fund_performance_search">saw </a>a -2.52% return on an equal-weighted basis in the first quarter, trailing its own 3-year and 5-year annualized returns of 7.10% and 10.90%, respectively. The world's most famous value investor remains heavily concentrated &#8211; 89% of his $258 billion portfolio sits in the top 10 holdings &#8211; but that concentration didn't provide a cushion in a volatile quarter.
Carl Icahn fared even worse. The activist legend posted a brutal -10.15% quarterly return &#8211; by far the worst among the billionaire cohort. Despite nearly 98% portfolio concentration, Icahn&#8217;s equal-weighted decline highlights how even conviction bets can backfire. His 5-year return of 15.99% is respectable, but the near-term pain is undeniable.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Soros, known for macro mastery, couldn't escape the downturn either. His fund returned -1.81%, despite maintaining a more diversified approach across 287 holdings. While Soros&#8217; 3-year return of 13.11% remains solid, the first quarter slip suggests even global tacticians weren't spared by the market's crosscurrents.
Bill Ackman's Pershing Square also struggled, dropping -2.72% in the first quarter. With a razor-sharp portfolio of just 12 holdings &#8211; and an eye-popping 99.5% concentration &#8211; Ackman's approach didn't offer much defense this quarter. His 5-year annualized return of 16.88% still towers over peers, but the first quarter was a rare off note.
Bottom line? 
The billionaire investors who thrived on bold bets and long-term conviction were handed a reality check. The first quarter wasn't about who&#8217;s biggest &#8211; it was about who could adapt. And for once, the billionaires blinked.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">Ray Dalio&#8217;s Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Buffett, Ackman, Icahn Take A Beating As Billionaires Weather Q1 Chaos

Nabors Industries shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and cut its price target from $53 to $28.

Financing

Press Releases

iQIYI Prices Upsized Offering of US$350 Million Convertible Senior Notes due 2030 and Announces Concurrent Repurchases of Approximately $300 Million Convertible Senior Notes

iQIYI Announces the Closing of Its Offering of US$350 Million Convertible Senior Notes due 2030 and Concurrent Repurchase of Approximately US$300 Million Existing Convertible Senior Notes

Entertainment

iQIYI showcases strategic response to TV drama industry trends: short-form content and technological innovation drive growth

iQIYI announces the groundbreaking of its first comprehensive theme park, leveraging IP-driven offline experiences to boost growth

iQIYI hosts Glittering Night to drive high-quality development in mini and short drama industry

iQIYI Files Its Annual Report on Form 20-F

From screen to society: latest iQIYI-presented films champion realism in cinematic storytelling

iQIYI leads agile, IP-and tech-powered offline experience with plan for second theme park in China

iQIYI to Report First Quarter 2025 Financial Results on May 21, 2025

iQIYI 2025 World Conference: Shaping the future of online entertainment through integrated "long + short" storytelling and enhanced IP monetization

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Media

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Vivid Seats

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

iQIYI

iQIYI (IQ) Opzioni

iQIYI (NASDAQ:IQ) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO